Podcasts about glioma

In this podcast, experts Manmeet Ahluwalia, MD, MBA; and Ashley S. Margol, MD, MS; discuss targeted therapies for adult and pediatric low-grade gliomas, pediatric diffuse midline glioma, and adult glioblastoma.

Host/Interviewee: Shahad Abdulsahib, PhD Graduate, UT Health San Antonio Description: Shahad Abdulsahib discusses the phase 1/2 BT008NA clinical trial evaluating microbubble-enhanced transcranial focused ultrasound combined with temozolomide in patients with newly diagnosed high-grade glioma, with findings published in The Lancet Oncology in December 2025

Glioma research has evolved rapidly over the past decade, driven by breakthroughs in molecular biology, imaging technologies, and computational tools. Today, clinicians can classify tumors with far greater precision than ever before, using genetic mutations, epigenetic markers, and advanced diagnostic frameworks. Yet, despite this progress, an important question remains: are we truly capturing the full picture of what shapes patient outcomes? Traditionally, glioma classification has focused on what can be measured in the tumor itself—its histology, molecular profile, and biological behavior. While these factors are undeniably critical, they may not fully explain why patients with similar tumors can experience very different clinical trajectories. Increasingly, researchers are beginning to recognize that broader influences—particularly social and environmental factors—may also play a role. Understanding how these different layers of information connect is becoming an important challenge in neuro-oncology. A review was published in Volume 17 of Oncotarget on March 31, 2026, titled “Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.” The study was led by first and corresponding author Kayode Ahmed from The University of Texas MD Anderson Cancer Center, in collaboration with Juan E. Núñez-Ríos from Universidad Panamericana. Full blog - https://www.oncotarget.org/2026/05/05/mapping-the-hidden-structure-of-glioma-research-what-are-we-missing/ Paper DOI - https://doi.org/10.18632/oncotarget.28851 Correspondence to - Kayode Ahmed - kmahmed@mdanderson.org Abstract video - https://www.youtube.com/watch?v=v8h2z3eEMFM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28851 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, glioma research, social network analysis, socio-clinical domains, web of science, networks To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The experts on this guideline podcast discuss updated recommendations for radiation therapy in the treatment of patients with Low Grade Gliomas (LGG) as well as the impact of newer WHO molecular classifications of LGG. J. Bradley Elder, MD Simon S. Lo, MD

BUFFALO, NY – April 6, 2026 – A new #review was #published in Volume 17 of Oncotarget on March 31, 2026, titled “Bibliometric mapping of glioma classification research through main path, key route, and K-core analyses.” Led by first and corresponding author Kayode Ahmed from The University of Texas MD Anderson Cancer Center, and Juan E. Núñez-Ríos from Universidad Panamericana, the study uses bibliometric network analysis to map how glioma classification research has evolved across clinical, molecular, and social domains. The authors analyzed Web of Science data using direct citation networks and applied main path analysis, key route analysis, and K-core analysis to identify influential papers, critical routes, and densely connected thematic clusters. The network comprised 46,204 nodes and 231,432 arcs, highlighting the prominent role of DNA methylation profiling in molecular biomarker-based classification models. The authors also found that advanced imaging and molecular techniques were key drivers of the field, while the subset of glioma classification studies that incorporate social factors remained relatively scarce. Their analysis, therefore, points not only to the major intellectual structure of the literature but also to a thematic gap in how social determinants are represented in glioma classification research. “Through quantitative network analysis complemented by narrative interpretation, we uncovered patterns and substructures that offer deep insights into the evolving research landscape.” The authors conclude that their framework offers a more integrative view of glioma classification research than approaches centered only on citation counts or h-index–style metrics. By identifying the evolutionary logic of the field and the limited but notable presence of social factors, the study suggests future glioma classification models may benefit from incorporating clinical, molecular, and social dimensions more explicitly. DOI - https://doi.org/10.18632/oncotarget.28851 Correspondence to - Kayode Ahmed - kmahmed@mdanderson.org Abstract video - https://www.youtube.com/watch?v=v8h2z3eEMFM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28851 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, glioma research, social network analysis, socio-clinical domains, web of science, networks To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Send us Fan MailPaper Discussed in this Episode:The Performance of Artificial Intelligence in Classifying Molecular Markers in Adult-Type Gliomas Using Histopathological Images: Systematic Review. Almaabreh O, Al-Dafi R, Tabassum A, Othman A, Abd-alrazaq A. J Med Internet Res 2026; 28: e78377.Episode Summary: In this deep dive of the Digital Pathology Podcast, we explore the intersection of human limitations and computational power. Following the 2021 World Health Organization mandate requiring molecular data to diagnose adult-type gliomas, pathology has faced a massive bottleneck. Can artificial intelligence look at a standard pink-and-purple tissue slide and accurately predict hidden genetic mutations to serve as a diagnostic shortcut? We unpack a massive 2026 systematic review that evaluates the architectures, the "data diets," and the structural hurdles of using AI to "see the invisible".In This Episode, We Cover:• The 2021 WHO Diagnostic Shakeup: How the World Health Organization shifted glioma diagnosis from pure visual morphology (judging a book by its cover) to requiring precise genetic spelling (finding a typo on page 42), making the diagnostic process incredibly slow and expensive.• The Targets - IDH vs. 1p/19q: Why AI models are highly proficient at spotting the metaphorical "canyon" carved by early metabolic IDH mutations, but struggle to find the subtle visual clues of 1p/19q chromosomal codeletions.• The AI Toolkit - CNNs, MIL, and Transformers: ◦ CNNs (like DenseNet121): The heavy lifters of medical imaging, analyzing local cell structures and edges by constantly reusing foundational visual features. ◦ Multiple Instance Learning (MIL): The brilliant algorithmic solution to the excruciating human labor of pixel-by-pixel tumor annotation, allowing the AI to mathematically figure out what cancer looks like using only slide-level labels. ◦ Hybrid Models: By combining the microscopic focus of CNNs with the zoomed-out, global contextual awareness of Transformers, these models achieved the highest average accuracy at 92.80%.• The "Data Diet" and Domain Shift: The critical danger of training AI exclusively on single, homogeneous databases like the TCGA. We discuss why an algorithm that performs perfectly in a pristine "test kitchen" completely panics and drops in performance when faced with the varied stains, slice thicknesses, and scans of real-world community hospitals.• Multimodal Medicine: The revelation that AI models perform vastly better when fed diverse data streams, such as combining slide images with MRI scans and clinical notes. Implementing this necessitates a monumental structural integration between historically siloed hospital departments like radiology and pathology.Key Takeaway: AI is not replacing pathologists tomorrow; it is stepping into the co-pilot seat. While hybrid models show immense promise, their true standalone clinical adoption depends on breaking free from narrow training data, overcoming domain shift, and fundamentally restructuring our hospitals to feed these algorithms the multimodal context they need to thriveSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

Dr. John Fortunato interviews Dr. Stefania Picariello and Dr. Enrico Opocher on their manuscript, entitled "Visual morbidity, long-term outcome, and prognostic factors in infants and young children with optic pathway low-grade glioma."

Podcast Host and Interviewee: Shahad Abdulsahib, PhD Candidate, UT Health San Antonio Podcast Description: Shahad Abdulsahib discusses a recent Phase 1 clinical trial on Rhenium-186 nanoliposome therapy for recurrent glioma, published in Nature Communications in March 2025.

Dr. Nathan Dalton interviews Dr. Joseph Sia on the topic of radiation hypofractionation – its history, current clinical landscape, and potential future developments for patients with gliomas.

Dr. Dave Rogawski interviews Dr. David Solomon on his research that sheds light on how key genomic alterations in high-grade glioma evolve over time and how these insights might inform therapeutic development.

Dr. Haseeb Mehmood discusses the use of microbubble-enhanced transcranial focused ultrasound combined with standard temozolomide in high-grade glioma.

Do you know how to implement novel targeted therapies into the glioma treatment algorithm? Join us to find out more!   Credit available for this activity expires: 1/6/2027 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003198?ecd=bdc_podcast_libsyn_mscpedu

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/TBU865. CME/MOC/AAPA credit will be available until December 20, 2026.Next-Generation Solutions to Optimize Glioma Care: Applying The Latest Evidence on Molecularly Targeted Therapies in IDH-Mutant Disease In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and American Brain Tumor Association. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Servier Pharmaceuticals LLC.Disclosure information is available at the beginning of the video presentation.

In today's episode, we passed the mic to Kathryn S. Nevel, MD; and Michael Veronesi, MD, PhD, who led an OncLive Ask the Expert discussion on evolving imaging strategies in glioma. 

Do you know how to integrate IDH inhibitors into the glioma treatment algorithm? Join our expert panel as they discuss complex real-world cases and more! Credit available for this activity expires: 12/19/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003175?ecd=bdc_podcast_libsyn_mscpedu

In episode 99 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Andrew Peters, Team Heroes cyclist and Division Manager at Republic National Distributing Company. Tune in as Andrew shares about surviving brain cancer, leaning on faith and good health habits to get through hard times, and how he's giving back to others facing a similar battle.

Join the program for an in-depth discussion on low-grade glioma – from burden and diagnosis to therapies. Credit available for this activity expires: 12/10/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/pediatric-low-grade-glioma-braf-alterations-stories-science-2025a1000x3w?ecd=bdc_podcast_libsyn_mscpedu

Patrick Y. Wen, MD, Dana-Farber Cancer Institute, Boston, MA, discusses current standards of care for low- and high-grade gliomas, including the importance of comprehensive molecular testing, the World Health Organization classification of tumors of the central nervous system, and newly available therapies. 

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Cassie Kline, MD, MAS, about updated efficacy data from the phase 2 FIREFLY-1 study (NCT04775485) of tovorafenib (Ojemda) in patients with relapsed/refractory pediatric low-grade glioma (pLGG) that were presented at the 2025 Society of Neuro-Oncology Annual Meeting. Dr Kline is an attending physician and director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia in Pennsylvania. In our exclusive interview, Dr Kline discussed longer-term efficacy and safety data from the trial, noting the sustained response rates, continued tumor shrinkage, and rates of patients who remained treatment free after approximately 36 months of follow-up. _____ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn. This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

How might the advent of IDH inhibitors impact the practice of radiation oncologists and their role within the wider multidisciplinary team? Credit available for this activity expires: 11/20/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/highlights-san-francisco-evolving-role-radiation-oncologist-2025a1000uyk?ecd=bdc_podcast_libsyn_mscpedu

Just a few days after complaining of a headache and vomiting on his way to school the next day in August of 2017, Gunner Smith, who was a 4th grade student was having emergency brain surgery at the Vanderbilt University Medical Center, after being diagnosed with a High Grade Multi Form Glioma. This operation was so serious that there was a question as to whether Gunner would even be able to wake up from this surgery. Gunner's parents Brittany and Brandon will talk about their son who showed so much bravery while he fought his disease and uttered these words after his diagnosis. "We Got This." Gunner passed away from this Pediatric Brain Cancer on May 28th of 2021.

Jannell and Keith Royer's daughter McKenna was experiencing headaches before her Diffuse Midline Glioma diagnosis in August of 2023. This Pediatric Brain Cancer behaves in a similar manner to DIPG, leaving little room for a lifespan which is normally expected to be 9-12 months.  McKenna did not even make it that far, passing away on February 26th of 2024, 6 months after being diagnosed. Jannell and Keith will talk about how McKenna felt surprisingly well during almost all of her battle, until 8 days before her passing when she suddenly went downhill health wise. Jannell and Keith will also about their Brave Like McKenna Foundation and their advocacy work for the cause of Pediatric Cancer.

What was thought to be a stomach ailment for Meryl Summers 1st grade daughter Adelia became much more than that in February of 2023 when she was diagnosed with the Pediatric Brain Cancer Diffuse Midline Glioma. Adelia was called the Wonder Girl for so many reasons during her 15 month battle with this disease which very sadly ended with her passing on May 30th of 2024. Since that time, Meryl has become a fierce advocate for the cause of Pediatric Brain Cancer and has testified in the Massachusetts State House for a bill which recognizes the cause of Pediatric Cancer be passed and signed into law as soon as possible. 

In today's episode, supported by Chimerix, we spoke with Patrick Y. Wen, MD, about the FDA approval of dordaviprone (Modeyso) for the treatment of adult and pediatric patients at least 1 year of age with H3K27M-mutated diffuse midline glioma who have progressive disease following prior therapy. Dr Wen is the director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute; as well as a professor of neurology at Harvard Medical School in Boston, Massachusetts. In our conversation, Dr Wen discussed the significance of this accelerated approval across patient age groups, key efficacy and safety data that supported this approval, and the importance of biomarker testing in patients with glioma. He also highlighted potential next steps for expanding the investigation of dordaviprone in patients with glioma and emphasized the ways that multidisciplinary collaboration can provide patients with personalized, optimized care. 

Dr. Maya Graham interviews Dr. Jessica Foster about her and her team's recent manuscript, entitled "Transient mRNA CAR T cells targeting GD2 provide dose-adjusted efficacy against diffuse midline glioma and high-grade glioma models". This work was published online in Neuro-Oncology in May 2025.

Wyatt Amaral, 9 months old, glioma, Whitman, with parents Becca and Denis Amaral ● When Wyatt was 3 months old, his parents noticed that his head was rapidly growing. His head grew from the 17th percentile to the 99th percentile. X-rays revealed he had tumors in his brain. His treatment has included multiple surgeries and chemotherapy and he is expected to complete treatment in July of next year. Today he is tumor free. ● Wyatt enjoys developing new skills like standing and jumping, playing with his 4 cats. He loves trying new foods and salmon is his favorite food. He has twin cousins who he enjoys playing with as well. ● His parents are so appreciative of the Jimmy Fund Clinic for all of their support and help throughout a difficult process.

Neurologist Michelle Monje studies the close relationship between cancer and the nervous system, particularly in an aggressive brain cancer that often strikes in childhood. Her research shows that the cancer cells are electrically integrated into the brain itself and these connections actually help the cancer to grow. Monje and collaborators have now developed an immunotherapy that has shown great promise in mice and early human trials. One patient had a “complete response” and is cancer-free four years after treatment, Monje tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Michelle MonjeConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Michelle Monje, a professor of pediatric neurology at Stanford University.(00:03:39) Focus on Cancer ResearchMonje's clinical observations led to exploring cancer-neuron interactions.(00:05:28) Neurons and Glial CellsThe role of neurons and glial cells in brain function and disease.(00:08:32) Gliomas in ChildrenAn overview of gliomas and their origins in glial precursor cells.(00:10:12) Rethinking Brain Cancer BehaviorHow gliomas don't just grow—they integrate with brain circuits.(00:14:49) Mechanisms of Tumor GrowthTwo primary mechanisms by which cancer exploits the nervous system.(00:16:32) Synaptic Integration of Cancer CellsThe discovery that glioma cells form synapses with neurons.(00:20:06) CAR T-Cell TherapyAdapting CAR T-cell immunotherapy to target brain tumors.(00:22:52) Targeting GD2 AntigenIdentification of a surface marker enables precision CAR T-cell therapy.(00:24:35) Immune Access to the BrainThe ability of CAR T-cells to reach the brain, despite prior understanding.(00:26:16) First Clinical Trial ResultsThe significant tumor reduction and response from CAR T-cell therapy.(00:28:21) Combined TherapiesPairing immune therapy with neural signaling blockers for better outcomes.(00:30:35) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook

Joining Dr. Buck Joffrey this week, Dr. Bobby Mukkamala shares his journey from aspiring cardiothoracic surgeon to becoming the president of the American Medical Association. He discusses his personal health challenges, including a brain tumor diagnosis, and how it has shaped his perspective on healthcare. The conversation delves into the importance of preventative medicine, the impact of the Flint water crisis, and the role of the AMA in shaping the future of healthcare, particularly in the realm of longevity and AI. Dr. Mukkamala emphasizes the need for a shift from reactive to proactive healthcare and addresses the challenges posed by influencer medicine and misinformation. Learn more about Dr. Bobby Mukkamala: https://www.ama-assn.org/about/board-trustees/bobby-mukkamala-md - Download Dr. Buck Joffrey's FREE ebook, Living Longer for Busy People: https://ru01tne2.pages.infusionsoft.net/?affiliate=0 Book a FREE longevity coaching consultation with Dr. Buck Joffrey: https://coaching.longevityroadmap.com/

Discover breakthrough targeted therapies for IDH-mutant gliomas and transform patient care with evidence-based approaches.   Credit available for this activity expires: 7/2/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002677?ecd=bdc_podcast_libsyn_mscpedu

Featuring an interview with Dr Patrick Y Wen, including the following topics: Glioma classification (0:00) Efficacy and safety of vorasidenib in the management of IDH-mutant gliomas (4:50) Case: A woman in her early 30s with a Grade 2 astrocytoma and an IDH R132H mutation and residual disease postoperatively (11:55) Case: A man in his early 40s experiencing stable disease with vorasidenib after subtotal resection (21:46) Ongoing trial investigating vorasidenib in IDH-mutant gliomas (27:30) Current and emergent strategies for the management of glioblastoma (31:27) Optimizing patient care and quality of life (46:24) CME information and select publications

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Patrick Y Wen, including the following topics: Classification and pathologic diagnosis of gliomas (0:00) Role of IDH inhibitors in the management of low-grade gliomas (6:37) Ongoing trials and remaining questions in the management of IDH-mutant gliomas (19:53) CME information and select publications

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.

Dr. Evan Noch interviews Dr. Marion Mateos about her and her team's recent manuscript entitled: "Germline analysis of an international cohort of pediatric diffuse midline glioma patients", published online in Neuro-Oncology in March 2025.

Dr. Iyad Alnahhas interviews Drs. Cynthia Hawkins and Arun Vadivel about their recent manuscript entitled: "The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases", published online in Neuro-Oncology in February 2025.   More Information

Description: Dr. Evan Noch interviews Drs. Cecile Riviere-Cazaux and Terry Burns about their recent manuscript entitled: "A field resource for the glioma cerebrospinal fluid proteome: impacts of resection and location on biomarker discovery", published online in Neuro-Oncology in December 2024.   Link: https://doi.org/10.1093/neuonc/noae277  

Description: Dr. Ankush Bhatia interviews Drs. Macarena de la Fuente and Mehdi Touat about their recent manuscript entitled: "The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma" published online in Neuro-Oncology in December 2024.   Link: https://doi.org/10.1093/neuonc/noae259

BUFFALO, NY — March 3, 2025 — A new #research paper was #published in Aging (Aging-US) on February 27, 2025, as the #cover of Volume 17, Issue 2, titled “Variability in radiotherapy outcomes across cancer types: a comparative study of glioblastoma multiforme and low-grade gliomas.” An international research team, led by first author Alexander Veviorskiy from Insilico Medicine AI Limited, Abu Dhabi, UAE, and corresponding author Morten Scheibye-Knudsen from the Center for Healthy Aging, University of Copenhagen, investigated how radiotherapy affects survival in different types of cancer, with a special focus on glioblastoma multiforme (GBM) and low-grade gliomas (LGG). Their findings reveal that radiotherapy has opposite effects in GBM and LGG patients. The study highlights key biological differences between these brain cancer types, emphasizing the need for personalized treatment strategies. Radiotherapy is a standard treatment for many tumors, but its effectiveness varies widely depending on the type of cancer. The researchers began by analyzing data from 32 cancer types using information from The Cancer Genome Atlas (TCGA). They then focused on glioblastoma multiforme (GBM) and low-grade gliomas (LGG), two types of brain cancer with distinct biological behaviors. GBM is an aggressive cancer with poor survival rates, whereas LGG progresses more slowly and often has a better prognosis. “GBM and LGG are particularly interesting to study together because GBM often originates from a preexisting LGG, representing a progression from a lower-grade to a higher-grade malignancy.” The results revealed a striking contrast: patients with GBM who received radiotherapy lived longer, whereas those with LGG had shorter survival times after treatment. To understand the reasons behind this, the researchers analyzed gene expression and signaling pathways. They identify several biological processes that may influence radiotherapy outcomes. For example, GBM tumors have weaker DNA repair mechanisms, making them more vulnerable to radiation-induced damage, which allows radiotherapy to effectively kill cancer cells. In contrast, LGG tumors have stronger DNA repair systems, helping cells survive radiation better and potentially reducing the treatment's effectiveness. Additionally, differences in immune system activity and genetic mutations—such as EGFR alterations—were linked to worse survival in LGG patients who received radiotherapy. These findings highlight the need for a more personalized approach to treating brain cancer. The study proposes that a universal approach to radiotherapy is not appropriate, particularly for patients with LGG. Instead, personalized treatment strategies based on genetic and molecular characteristics could improve patient survival outcomes. The research also raises the possibility of combining radiotherapy with targeted therapies, such as immune-boosting therapies or DNA repair inhibitors, to enhance its effectiveness. In conclusion, this study highlights the complexity of brain cancer treatment and the need for further research to refine therapeutic strategies. By understanding the molecular and genetic differences between the different types of cancers, more effective and personalized approaches can be developed to improve survival and quality of life for brain cancer patients. DOI - https://doi.org/10.18632/aging.206212 Corresponding author - Morten Scheibye-Knudsen - mscheibye@sund.ku.dk Video short - https://www.youtube.com/watch?v=j91rzDJHXTE Visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

In this week's podcast, Neurology Today's editor-in-chief highlights articles on the pros and cons of virtual neurology education, the FDA approval of tirzepatide for obesity-related obstructive sleep apnea, and the promise of AI for glioma assessment.  

In this episode of Brain Tumor Talk, we dive into the world of biomarker testing—a powerful tool in brain tumor diagnosis and treatment. With the 2021 World Health Organization (WHO) classification emphasizing the role of molecular biomarkers, understanding tumor profiling is more crucial than ever. Shwetal Mehta, PhD, and Charuta Furey, MD, join us on the episode to break down the science in an accessible way that empowers patients.Tune in to learn the essentials, so you're ready to discuss biomarker testing with your care team.Learn more: https://www.ivybraintumorcenter.org/Follow Ivy Brain Tumor Center on Social: Instagram | Facebook | Twitter | LinkedInSign up for our monthly newsletter to stay informed about the latest in brain tumor research, treatment and community events.Request a No-Cost Clinical Trial Screening: https://www.ivybraintumorcenter.org/brain-tumor-clinical-trials/trialeligibility/ The information shared on this podcast is for educational and informational purposes only and serves as a starting point for you to have a conversation with your personal healthcare provider. Nothing stated on this podcast should be considered medical advice. You should always consult your personal physician or healthcare provider regarding your specific health concerns before beginning or changing any treatment plan. The views, opinions, and positions expressed by the host and guests on this podcast are theirs alone and do not necessarily reflect the views, opinions or positions of th...

Dr. Evan Noch interviews Drs. Pravesh Gupta and Krishna Bhat about their recent manuscript entitled "Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas", published online in Neuro-Oncology in August 2024 Read Paper

Article - The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists'Clinical Decision-Making in Patients With Posttreatment High-GradeGlioma: A Prospective Survey-Based Study Atefeh Zeinoddini, MD, discusses the AJR article by Dagher et al. exploring the impact of advanced neuroimaging on management decisions after treatment for high-grade glioma, based on surveys of neurooncologists.

Teri Gaberman's son Aaron was diagnosed with a rare form of Pediatric Brain Cancer when he was 10 years old in 2005. The next year Aaron contacted former New York Yankee great Bobby Murcer who had been diagnosed with a Glioma type of Brain Cancer at the end of 2006 and that started an incredible friendship which lasted until Bobby passed away on July 8th of 2008. Teri will talk about her son's amazing life and her Berni and Mercer non- profit which has helped and is helping so many in the Pediatric Cancer community.

Weston Hermann was first diagnosed with a very rare form of a Glioma type of Pediatric Brain Cancer when he was 7 years old in 2014 and is now going through his 5th battle with this disease within the last 10 years. His father Jared will talk about the amazing fight that Weston has been through and that his resilience has allowed him to still be able to perform as a well known and well regarded 17 year old hockey player , despite playing many games while going through a chemotherapy regiment. 

With new advances in the treatment of brain cancer, patients have more options than ever. This week, Faith talks with Dr. Kathryn Beal, a radiation oncologist at NewYork-Presbyterian and Weill Cornell Medicine, to explore how breakthroughs in immunotherapy and stereotactic radiosurgery can successfully treat metastatic cancer in the brain. In recognition of Glioblastoma Awareness Day, Dr. Beal also explains treatment options for gliomas, and her hope for the future for patients with brain tumors and brain metastases.